Report Cards and Feedback for PCCE
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, Los Angeles
About this trial
As part of UCLA Health's commitment to developing an integrated health system built on a foundation of physician-led, team-based primary care, the Department of Medicine (DOM) implemented a performance-based incentive plan called the Primary Care Clinical Excellence (PCCE) Incentive Plan.
The UCLA Health DOM Quality team is leading the implementation and evaluation of this incentive plan across the UCLA Health primary care network, with the primary goal to immediately produce improvements in the quality of primary care. In order to rigorously measure the most efficacious ways to frame and communicate information about the quality improvement (QI) program, the DOM Quality team has partnered with the UCLA Anderson School of Management.
Understanding the factors that motivate physicians to deliver high quality primary care will provide pivotal insights into the successful implementation of performance based programs nationwide.
Eligibility criteria
Qualifiers
Primary care physicians within the UCLA Health Department of Medicine Primary Care Network that are eligible for the PCCE Incentive program as of October 1, 2023.
Physicians with the clinical full-time employee level (FTE) of ≥ 40% as of October 1, 2023
Physicians with panel size >50 patients as of October 1, 2023
Disqualifiers
Physicians classified as Pediatrics will be excluded from data analysis given the structural differences in health maintenance guidelines for children.
Physicians classified as Urgent Care will be excluded from data analysis given the structural differences in their performance evaluation. They are all in Arm 1.
Physicians who participate in the design of this experiment will be excluded from analysis.
Trial design
Treatments tested in this trial
- Standard Communication Email
- Personalized Report Card Email
- Bottom-Up Framing
Treatment groups
330 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov